Search clinical trials for: Technosphere® Insulin Inhalation Powder

Total 640 results

Mannkind Corporation

Completed

A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro

Diabetes Mellitus: Type 1

United States
Mannkind Corporation

No longer available

Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder

Type 1 Diabetes | Type 2 Diabetes

United States
Mannkind Corporation

Completed

Pharmacokinetic Study in Healthy Volunteers

Healthy Volunteers

United States
Mannkind Corporation

Completed

Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes

Diabetes, Type 2 | Diabetes, Type 1

United States, Spain, Canada, Russian Federation, Czech Republic, Poland, Ukraine, United Kingdom
Mannkind Corporation

Completed

An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial

Type 2 Diabetes Mellitus

United States, Czech Republic, Bulgaria, Germany
Mannkind Corporation

Completed

Clamp Study Comparing Inhalation of Technosphere®/Insulin in Smokers and Non-Smokers With Type 2 Diabetes

Diabetes Type 2

United States
Mannkind Corporation

Completed

Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes

United States, Russian Federation, Brazil, Ukraine
Mannkind Corporation

Completed

A 2-Month Safety Follow-Up Trial

Type 1 Diabetes | Type 2 Diabetes

United States, Brazil, Canada, Russian Federation
Mannkind Corporation

Terminated

Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler

Type 2 Diabetes

United States
Mannkind Corporation

Completed

Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes

Type 1 Diabetes Mellitus

United States
Mannkind Corporation

Terminated

Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166

Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

United States
South Orange County Endocrinology
Mannkind Corporation

Withdrawn

Single Site, Single Subject, Treatment IND With Mannkind Corporation's Technosphere Inhalation System

Diabetes

United States
Mannkind Corporation

Completed

A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Netherlands
Mannkind Corporation

Completed

Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere® Insulin (TI) Using the Gen2C Inhaler

Healthy

United States
Mannkind Corporation

Completed

Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney Function

Diabetes Mellitus | Mild Nephropathy | Moderate Nephropathy

United States
Mannkind Corporation

Completed

Compare the Same Dosage of Insulin Using a Combination of Cartridges, 30 Units as 2 Cartridges vs. 1 Cartridge

Healthy Volunteers

United States
Mannkind Corporation

Completed

Afrezza With Basal Combination (ABC)

Type 1 Diabetes

United States
Mannkind Corporation

Completed

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

Diabetes Type 2

Brazil, Spain, United States, Argentina, Canada, Chile, Mexico, Poland, Russian Federation, United Kingdom
Mannkind Corporation

Completed

Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period

Type 1 Diabetes Mellitus

United States, Brazil, Russian Federation, Ukraine
Mannkind Corporation

Completed

A Study to Evaluate Insulin in the Blood After Inhalation of a Dry Powder Insulin Formulation (Called Technosphere®/Insulin) in Non-diabetic Patients With & Without Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Netherlands, United States, Austria, United Kingdom
Sansum Diabetes Research Institute
Juvenile Diabetes Research Foundation

Completed

Feasibility Study Using Zone-MPC Controller, HMS and Technosphere® Insulin Inhalation System From MannnKind Corp

Type 1 Diabetes Mellitus

United States
Mannkind Corporation

Completed

Comparison of the Effect on the Glucose Infusion Rates Between Inhaled Technosphere Insulin and a Subcutaneous Injection of Regular Human Insulin

Healthy
Mannkind Corporation

Completed

Study of the Efficacy and Safety of Inhaled Technosphere Insulin in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus
Mannkind Corporation

Completed

PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM)

Type 1 Diabetes Mellitus

Germany
Mannkind Corporation

Terminated

Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease

Type 2 Diabetes Mellitus | Asthma | Type 1 Diabetes Mellitus | Moderate Chronic Obstructive Pulmonary Disease

United States, Russian Federation, Ukraine
Mannkind Corporation

Completed

18-Week, Randomized, Double-blind, Placebo Controlled, Forced Titration Study of Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus
Mannkind Corporation

Completed

Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Brazil, Spain, Argentina, Canada, Chile, Mexico, Poland, Russian Federation, Ukraine, Czech Republic
Mannkind Corporation

Terminated

Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

United States
Eli Lilly and Company
Alkermes, Inc.

Completed

Study of Human Insulin Inhalation Powder in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany, Italy, Puerto Rico, Hungary, Mexico, United States, India, Portugal, Taiwan, Brazil, Poland
Eli Lilly and Company

Completed

A Concordance Study Comparing Insulin Treatments in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Puerto Rico, Russian Federation, Canada, Denmark, India, Poland, Korea, Republic of, Brazil, Argentina, Mexico, South Africa
Eli Lilly and Company
Alkermes, Inc.

Completed

Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD

Diabetes Mellitus | Pulmonary Disease, Chronic Obstructive | Asthma

United States, Argentina, India, Bulgaria, Canada, Chile, Colombia, Croatia, Hong Kong, Hungary, Mexico, Philippines, Puerto Rico, Singapore, Taiwan, Thailand
Eli Lilly and Company
Alkermes, Inc.

Completed

Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus.

Diabetes Mellitus, Type 1

United States
Eli Lilly and Company
Alkermes, Inc.

Completed

Study of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States, Belgium, Canada, Croatia, Hungary, India
Eli Lilly and Company
Alkermes, Inc.

Completed

Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Puerto Rico, Spain, United States, India, Brazil
Eli Lilly and Company
Alkermes, Inc.

Completed

Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany, Puerto Rico, United Kingdom, Spain, Canada, Brazil, Korea, Republic of, India, Israel, Russian Federation, South Africa
Eli Lilly and Company
Alkermes, Inc.

Completed

Evaluate the Efficacy of Insulin Patients With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States, Belgium, India, Italy, Argentina, France, Germany, Mexico, Puerto Rico
Eli Lilly and Company
Alkermes, Inc.

Completed

Compare Two Dosing Algorithms in Insulin-Naive Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Puerto Rico, United States, Spain, India, Belgium, Argentina, Austria, France, Mexico
Mannkind Corporation
Jaeb Center for Health Research

Active, not recruiting

Afrezza® INHALE-1 Study in Pediatrics (INHALE-1)

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

United States
Eli Lilly and Company
Alkermes, Inc.

Completed

A Study for Patients With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

Japan, Taiwan
AlgiPharma AS
Imperial College London; Cystic Fibrosis Foundation; University Hospital of Cologne and other collaborators

Withdrawn

A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis (SMR3372)

Cystic Fibrosis

Germany
Mannkind Corporation

Completed

Comparison Between Technosphere/Insulin Inhalation Powder Versus Rapid Acting Insulin in Subjects With Type 2 Diabetes Mellitus

Diabetes Type 2

Russian Federation
Mannkind Corporation

Completed

Effects of URI on Diabetic Subjects Utilizing Technosphere Insulin After a Meal Challenge

Diabetes Mellitus | Upper Respiratory Infection

United States, Russian Federation, Canada
Mannkind Corporation

Completed

A Study Comparing Subcutaneous Rapid Acting Insulin and One Formulation of Inhaled Insulin in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
Mannkind Corporation

Terminated

Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Asthma

Brazil, United States, Canada, Poland, Russian Federation, Argentina, Czech Republic, Mexico, Spain, Ukraine, United Kingdom
Mannkind Corporation

Completed

To Compare the Effect of Inhaled Insulin With Subcutaneously Injected Insulin in Subjects With Type 2 Diabetes Mellitus.

Diabetes Mellitus, Type 2

Germany
Chiesi Farmaceutici S.p.A.

Completed

Study to Investigate the Pharmacokinetics of CHF 6001 DPI Administered Via Nexthaler® Device or the Capsule for Oral Inhalation Via Aerolizer® Device

COPD

Belgium
University of Colorado, Denver
University of Southern California; Mannkind Corporation; Atlanta Diabetes Associates and other collaborators

Completed

Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study (STAT)

Diabetes Mellitus, Type 1

United States
Mannkind Corporation

Completed

A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine

Diabetes Mellitus, Type 1
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men

Asthma | Chronic Obstructive Pulmonary Disease COPD

United States
Mannkind Corporation

Completed

Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes

Diabetes, Type I

United States, Spain, Brazil, Argentina, Canada, Chile, Mexico, Poland, Russian Federation, United Kingdom

Search clinical trials for: Technosphere® Insulin Inhalation Powder

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations